Allergan (AGN) Declares $0.74 Quarterly Dividend; 1.6% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Nasdaq lags peers as Netflix, chip stocks drag; AmEx lifts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Wall St indexes split, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Jabil falls after placing CEO on paid leave amid internal investigation
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Ironwood Pharma (IRWD), Allergan (AGN) Settle LINZESS (linaclotide) Patent Litigation with Teva (TEVA)
January 22, 2020 9:21 AM ESTIronwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Teva Pharmaceuticals, USA (NYSE: TEVA) resolving patent litigation brought in response to Tevas abbreviated new drug application (ANDA) seeking approval to market generic versions of 145 mcg and 290 mcg LINZESS (linaclotide) prior to the expiration of the companies applicable patents. This settlement with Teva is the last of the remaining defendants in this patent... More
Wells Fargo Downgrades Allergen (AGN) to Equal Weight
January 22, 2020 4:29 AM ESTWells Fargo analyst David Maris downgraded Allergen (NYSE: AGN) from Overweight to Equal Weight with a price target of $198.00.
For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.
Shares of Allergen closed at $192.58 yesterday.
... More
